Manufacturer
KOTRA PHARMA (M) SDN. BHD.
Contents
Miconazole
Indication
Management of superficial candidiasis & fungal skin infections eg, mucocutaneous candidiasis, dermatophytosis & pityriasis versicolor.
Instruction
Apply to lesion bd, continue for at least 1 wk after lesion has completely healed to prevent relapse.
Drug interaction
May increase anticoagulant effect of warfarin. May increase serum concentrations or enhance the effects of phenytoin, fosphenytoin, sulfonylureas, saquinavir, vinca alkaloids, busulfan, docetaxel, Ca channel blockers (e.g. dihydropyridines, verapamil), immunosuppressants (e.g. ciclosporin, tacrolimus, sirolimus), carbamazepine, cilostazol, buspirone, disopyramide, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate.
Potentially Fatal: Increases the risk of cardiac arrhythmia with drugs known to prolong QT interval or induce torsade de pointes such as astemizole, cisapride, dofetilide, halofantrine, mizolastine, pimozide, quinidine, sertindole, and terfenadine. May increase risk of ergotism with necrosis of extremities with ergot alkaloids (e.g. ergotamine, dihydroergotamine). May inhibit metabolism of triazolam, oral midazolam and HMG-CoA reductase inhibitors (e.g. simvastatin, lovastatin).
Malaysia
